CLL cells from patients exhibited heterogeneous ex vivo adhesion patterns to stromal cells and demonstrated distinct sensitivity profiles to 5-LOX inhibitors compared to the BTKi ibrutinib. The gene discussed is LOX; the disease is B-cell chronic lymphocytic leukemia.